Genzyme Corp. (dba Sanofi Genzyme) has disclosed isoxazolidine compounds acting as receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of Alzheimer’s disease and multiple sclerosis, among others.
Recursion Pharmaceuticals LLC has described molecular glue degraders comprising DDB1- and CUL4-associated factor 15 (DCAF15) and RNA-binding protein 39 (RBM39) protein acting as RBM39 degradation inducers and RBM39/DCAF15 interaction inducers reported to be useful for the treatment of renal cell carcinoma.
Agenebio Inc. has identified benzodiazepine derivatives acting as GABA(A) receptor subunits α5β3γ2 (GABRA5) positive allosteric modulators reported to be useful for the treatment of mild cognitive impairment, amyotrophic lateral sclerosis, schizophrenia, post-traumatic stress, autism, substance abuse and dependence, Alzheimer’s disease and Parkinson’s disease, among others.
Beijing Neox Biotech Co. Ltd. has synthesized proteolysis targeting chimeras (PROTACs) comprising a cereblon (CRBN)-targeting moiety covalently bound to a Bruton tyrosine kinase (BTK)-targeting moiety through a linker reported to be useful for the treatment of cancer.
University of Toronto has described histone deacetylase 6 (HDAC6) inhibitors reported to be useful for the treatment of cancer and neurological disorders.
Shanghai Allist Pharmaceuticals Co. Ltd. has divulged protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
Suzhou Kintor Pharmaceuticals Inc. has identified protein degradation inducers reported to be useful for the treatment of cancer, viral infection, cardiovascular and cerebrovascular disorders.
Nerviano Medical Sciences Srl has synthesized Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer, diabetic nephropathy, organ transplant rejection, arthritis, fibrosis, inflammation, neurodegeneration and metabolic diseases.
RSS